Results 91 to 100 of about 15,511 (169)

HLA-B*5701 frequency in Chilean HIV-infected patients and in general population

Brazilian Journal of Infectious Diseases
It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior ...
Helena Poggi, Alejandra Vera, Marcela Lagos, Sandra Solari, Luis Rodríguez P, Carlos M Pérez   +5 more
doaj   +1 more source

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells

Pharmaceutics, 2011
Certain triple nucleoside/tide reverse transcriptase inhibitor (NRTI) regimens containing tenofovir (TDF) have been associated with rapid early treatment failure. The mechanism is unknown, but may be at the level of drug transport.
Saye H. Khoo, Omar Janneh
doaj   +1 more source

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children [PDF]

, 2007
: Objective: To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial. Design: PENTA 5 was a 48-week randomised controlled trial
COMPAGNUCCI A, LEVY J, FEITERNA SPERLING C, BUTLER K, WALKER AS, WINTERGERST U, GIBB DM, GIAQUINTO, CARLO, SAIDI Y, DE ROSSI, ANITA, HARPER L, CANDEIAS E, CASTELLI GATTINARA G, PILLAY D, DELLA NEGRA M, Paediatric European Network for the Treatment of AIDS, GREEN H   +16 more
core  

Gestational exposure to HIV drugs alters intestinal mucosa-associated microbial diversity in adult rat offspring

Experimental Biology and Medicine
The antiretroviral (ARV) drug combination of abacavir sulfate, dolutegravir, and lamivudine [ABC/DTG/3TC; Tri combination Anti-retroviral therapy (TC-ART)] has revolutionized HIV treatment by effectively targeting different stages of viral replication ...
Yaswanthi Yanamadala, Chandra Mohan Reddy Muthumula, Kuppan Gokulan, Kumari Karn, Vicki Sutherland, Helen Cunny, Janine H. Santos, Sangeeta Khare   +7 more
doaj   +1 more source

Monitoring Abacavir Bioactivation in Humans: Screening for an Aldehyde Metabolite

, 2013
The anti-HIV drug abacavir is associated with idiosyncratic hypersensitivity reactions and cardiotoxicity. Although the mechanism underlying abacavir-toxicity is not fully understood, drug bioactivation to reactive metabolites may be involved.
Pereira, S, Grilo, N, Marques, MM, Monteiro, E, Antunes, A, Oliveira, MC, Caixas, U, Marinho, A, Charneira, C   +8 more
core  

Uptake of [³H]abacavir by HUVECs.

, 2015
Uptake of [3H]abacavir (2 μCi/mL, 1 nM) by HUVECs was measured after incubation with [3H]abacavir with or without unlabeled abacavir (20 μM) for 1, 6, 12, and 20 min at room temperature. Values are means ± S.E.M.
Yiu Wa Kwan (362888), Cui Yang (282067), Simon Ming Yuen Lee (362891), Shun Wan Chan (362889), Maggie Pui Man Hoi (362887), Rachel Wai Sum Li (422494), George Pak Heng Leung (362890)   +6 more
core   +1 more source

Insights into regulatory T-cell and type-I interferon roles in determining abacavir-induced hypersensitivity or immune tolerance

Frontiers in Immunology
IntroductionClinical use of several small molecule drugs may lead to severe T-cell-mediated idiosyncratic drug hypersensitivity reactions (iDHR) linked to HLA alleles, including abacavir (ABC) with HLA-B*57:01.
Marco Cardone, Hratch M. Baghdassarian, Maryam Khalaj, Kirthiram Krishnaveni Sivakumar, SuJin Hwang, Sintayehu Gebreyohannes, Kazuyo Takeda, Yura Jang, Nathan E. Lewis, Nathan E. Lewis, Michael A. Norcross, Montserrat Puig   +11 more
doaj   +1 more source

Abacavir/lamivudine combination in the treatment of HIV: a review

Therapeutics and Clinical Risk Management, 2010
Geetha Sivasubramanian1, Emmanuel Frempong-Manso2, Rodger D MacArthur11Division of Infectious Diseases, Wayne State University, Detroit, MI, USA; 2University of Pittsburgh Medical Center, Shadyside Hospital, Pittsburgh, OH, USAAbstract: Abacavir has been
Geetha Sivasubramanian, Emmanuel Frempong-Manso, Rodger D MacArthur   +2 more
doaj  

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

BMC Infectious Diseases, 2005
Background Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-HIV medications without lipid effects. Method An open-label, randomized pilot study compared changes in fasting lipids and HIV-1 RNA in 104 HIV-infected adults
Snidow Jerry W, Wakeford John H, Williams Vanessa C, Olliffe Jeffrey F, Rodriguez Allan, DeJesus Edwin, Sension Michael G, Keiser Philip H, Shachoy-Clark Anne D, Fleming Julie W, Pakes Gary E, Hernandez Jaime E   +11 more
doaj   +1 more source

Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study

BMC Infectious Diseases, 2017
Background There is ongoing controversy regarding abacavir use in the treatment of HIV infection and the risk of subsequent development of cardiovascular disease. It is unclear how the risk varies as exposure accumulates.
Kunchok Dorjee, Sanjiv M. Baxi, Arthur L. Reingold, Alan Hubbard   +3 more
doaj   +1 more source